Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial

Ather Ali,¹ Theresa R Weiss,¹ Douglas McKee,² Alisa Scherban,¹ Sumiya Khan,¹ Maxine R Fields,¹ Damian Apollo,¹ Wajahat Z Mehal¹

To cite: Ali A, Weiss TR, McKee D, *et al.* Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. *BMJ Open Gastro* 2017;4:e000164. doi:10.1136/bmjgast-2017-000164

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjgast-2017-000164>).

Received 30 June 2017
Revised 26 July 2017
Accepted 18 August 2017

ABSTRACT

Background Patients with irritable bowel syndrome (IBS) are often placed on diets guided by food intolerance assays, although these have not been validated. We assessed the effects of individualised diets in patients with IBS guided by a leucocyte activation test.

Methods This is a parallel-group, double-blind, randomised controlled trial of 58 adults with IBS seen at an academic health centre in Northeast USA. Peripheral venous blood was analysed using a leucocyte activation test; individual foods were reported to produce positive or negative results. Participants were randomised to a 4-week diet with either individualised guidance to eliminate foods with positive assay results and allow foods with negative assay results (intervention), or with individualised guidance, matched in rigour and complexity, to eliminate foods with negative assay results and allow foods with positive assay results (comparison). The primary outcome was between-group differences in the IBS Global Improvement Scale (GIS). Secondary outcomes included reductions in IBS Symptom Severity Scale (SSS) scores and increases in IBS Adequate Relief (AR) and Quality of Life (QOL) scores. An aptamer-based proteomic analysis was conducted in strong responders.

Results The intervention group had significantly greater increases in mean GIS score after 4 weeks (0.86 vs comparison; 95% CI 0.05 to 1.67; $p=0.04$) and 8 weeks (1.22 vs comparison; 95% CI 0.22 to 2.22; $p=0.02$). The intervention group also had significantly greater reductions in mean SSS score at 4 weeks (−61.78 vs comparison; 95% CI −4.43 to −119.14; $p=0.04$) and 8 weeks (−66.42 vs comparison; 95% CI −5.75 to −127.09; $p=0.03$). There were no significant differences between intervention and comparison groups in mean AR or QOL scores. A reduction in neutrophil elastase concentration was associated with reduced symptoms.

Conclusions Elimination diets guided by leucocyte activation tests reduced symptoms. These findings could lead to insights into the pathophysiology of IBS.

Trial registration number NCT02186743.

INTRODUCTION

Irritable bowel syndrome (IBS) is a prevalent and costly condition that can be disabling. In the USA, 8%–20% of the population meets diagnostic criteria, with female predominance,¹ with direct and indirect costs

Summary box

What is already known about this subject?

- Over 60% of IBS patients report symptoms related to food, such as symptomatic exacerbations and improvement when avoiding these foods.
- Previous trials of elimination diets for irritable bowel syndrome (IBS) found varying levels of efficacy, with trials of the low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet demonstrating promise.
- No previous randomised trials have been published assessing the efficacy of leucocyte activation testing in IBS.

What are the new findings?

- Statistically significant benefits were seen in global improvement and in symptom severity in a 4-week diet guided by leucocyte activation testing compared to a matched sham diet.
- This study provides novel data suggesting that a leucocyte activation test can be used to develop an individualised diet that can alleviate symptom burden in IBS, distinct from other types of dietary interventions.
- A broad proteomic screen found a reduction in plasma elastase in strong responders to the intervention diet.

How might it impact on clinical practice in the foreseeable future?

- This study provides data suggesting that a leucocyte activation test can be used to develop an individualised diet that can alleviate symptom burden in IBS. These dietary changes may be less restrictive than a low-FODMAP diet and may result in better long-term adherence.

¹School of Medicine, Yale University, New Haven, Connecticut, USA

²Department of Economics, Cornell University, Ithaca, New York, USA

Correspondence to

Dr. Ather Ali; ather.ali@yale.edu

gold standard for diagnosing food intolerance.^{9 10} While clinically valid, this approach is rare outside academic contexts and largely impractical for practising clinicians.⁴

A number of commercially available blood tests claim to diagnose food intolerance,¹¹ and most remain largely unvalidated.¹² Among the more highly used¹³ are leucocyte activation tests, which are used to guide elimination diet recommendations, although no rigorous studies of leucocyte activation tests are in Medline-indexed journals. These tests are generally considered unproven diagnostic methods for detecting food allergy.¹⁴ In a survey of unconventional medical laboratory tests,¹³ some respondents noted that leucocyte activation testing is anecdotally reported to be of greater clinical value than other unconventional food intolerance assays.

Leucocyte activation tests culture peripheral blood leucocytes with standardised extracts of individual foods, utilising flow cytometry to detect morphological changes in leucocytes after exposure to food extracts, claiming to identify intolerance to the foods. Clinicians use these tests, then make targeted food elimination recommendations.

Here, results are reported from a rigorously controlled trial of a leucocyte activation test, adequately powered to assess clinical response in participants with IBS, compared with a matched, individualised, sham diet. The null hypothesis was that there would be similar responses to either elimination diet (consistent or inconsistent with test results), with no scientific basis to presume differential between-group effects.

METHODS

Ethics and trial registration

The study was approved by the Human Investigation Committee of Yale University (New Haven, Connecticut, USA). Data were collected at the Yale Center for Clinical Investigation outpatient facility. All participants provided written informed consent and received financial compensation. The protocol was registered on *clinicaltrials.gov* prior to enrolment (NCT02186743).

Study design

This was a parallel-group, randomised clinical trial with two arms allocated in a 1:1 ratio. The primary aim was to assess the efficacy of individualised 4-week diets in participants with IBS:

intervention—elimination diet consistent with leucocyte activation test results; versus comparison—elimination diet systematically inconsistent with test results, matched in rigour and complexity.

Participants

Adults 18–75 years of age meeting Rome III criteria for any subtype of IBS¹⁵ with active symptoms (SSS ≥ 150) were enrolled. Concurrent IBS medications (eg, fibre, antispasmodics, antidepressants, loperamide, and so on) and behavioural treatments were allowed if dosing was stable for 30 days prior to enrolment.

Exclusion criteria included a history of inflammatory bowel disease, abdominal surgeries, radiation proctitis, recent (within 30 days) antibiotic use, and current use of opioids/other analgesics (with the exception of non-steroidal anti-inflammatory drugs), anticoagulants, or immunosuppressives. Also excluded were persons unlikely to make dietary changes, who were operationally defined as eating outside of the home more than five times per week.

Interventions

Leucocyte activation test

On enrolment, a single sample of de-identified peripheral venous blood preserved in 3.8 sodium citrate was sent for testing at a commercial laboratory (Alcat Test; Cell Science Systems, Deerfield Beach, Florida, USA) via overnight courier. Leucocytes were separated from whole blood using a density gradient at high-speed centrifugation, and a neutral buffer and autologous plasma were added back to the cells, which were then aliquoted into a round-bottomed test wells or control wells containing 200 test food extracts or neutral buffer, respectively, and then incubated for 15 min, with 100 rpm rotation, at 37°C. Cell counts were performed using the electric sensing zone method (Coulter or impedance method) of particle sizing, distributing each cell into one of 256 size channels, thus creating a size/volume distribution curve, or histogram for each control and each test sample. Differences in morphology curves categorise foods as (1) *severe intolerance*, (2) *moderate intolerance* ((1) and (2) denoted as *positive* in this study), (3) *mild intolerance* (denoted as *mild*), or (4) *acceptable foods/no reaction* ((4) denoted as *negative* in this study).

Diet assignment

Participants were randomised (1:1) to receive the following:

1. Intervention: individualised diet consistent with test results.

Participants were instructed to avoid positive foods for the diet period (4 weeks). Participants were allowed to consume mild foods every fourth day, and negative foods ad libitum, consistent with usual clinical practice. Dietary instruction was delivered at baseline (in person; 30–45 min) by a blinded registered dietitian, and after 2 weeks (telephone; 15 min). After 4 weeks, participants were instructed to consume an ad libitum diet.

2. Comparison: individualised sham diet systematically inconsistent with test results.

Participants were instructed to avoid negative foods for the diet period (4 weeks). Participants were allowed to consume mild foods every fourth day and positive foods ad libitum. Dietary instruction was identical to the intervention group.

Assessments

Participants were assessed at baseline (the day prior to starting the diet), 4 weeks (the final day of the diet), and at 8 weeks postbaseline.

Assessment of global improvement, symptom severity, adequate relief, quality of life, and adherence

Primary outcome

The IBS Global Improvement Scale (GIS) is a validated assessment of IBS symptoms using a 7-point Likert scale ranging from 'substantially worse' to 'substantially improved' widely used in clinical trials.¹⁶ Improvement in the IBS-GIS is associated with satisfactory control of urgency, firmer stools, fewer stools per day, and fewer days with incomplete evacuation compared with non-responders.

The IBS Symptom Severity Scale (SSS) is a psychometrically valid and reliable instrument that contains five 100-point scales assessing the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distension, satisfaction with bowel habits, and interference with quality of life.^{17–23}

The IBS Adequate Relief (AR)²⁴ is a single-item question asking 'Over the past week have you had adequate relief of your IBS symptoms?'

The IBS Quality of Life (QOL) questionnaire²⁵ is a 34-item measure assessing the degree to which IBS interferes with quality of life. Each item is rated on a 5-point Likert scale and a linear transformation yields a 0–100 score, with higher scores indicating better quality of life.²⁵

Adherence

Participants were queried about the number of times restricted foods were consumed during the course of the 4-week intervention.

No changes were made to trial outcomes after the trial commenced.

Proteomic analysis

After initial data analysis, six intervention participants with the highest magnitude of improvement in the SSS (strong responders) were selected for proteomic analysis. Baseline and 4-week plasma samples were sent to SomaLogic (Boulder, Colorado, USA) for analysis of 1128 proteins.

Sample size

Based on results from Kaptchuk and Lembo assessing responses to placebo interventions in IBS,¹⁹ an analytic sample of 46 participants was calculated with 80% power to detect a between-group difference of 1.1 points (SD=1.3) on the GIS (two-sided; $\alpha=0.05$). Accounting for up to 25% attrition, 29 participants per arm were recruited (total n=58).

Randomisation

Participants were randomised in permuted blocks (size of 4) using the OnCore Enterprise Research System (Forte Research Systems, Madison, Wisconsin, USA). Allocation was concealed by restrictions in the software to all blinded study personnel.

Blinding and dietary instruction

All participants, investigators, and study personnel (besides the coordinator who assigned dietary

interventions) were blinded to allocation status. Participants were assessed individually. Data analysis commenced after all study assessments were complete and the database locked.

Dietitians maintained blinding to study arm using the following procedures:

On enrolment, blood was drawn for eligibility screening and leucocyte activation testing. Test results were electronically transmitted to the coordinator (TRW), and eligible participants were then scheduled for dietary instruction. Prior to the dietitian visit, the coordinator electronically sent the dietitian each participant's list of positive, mild, and negative foods.

In order to create a sham diet control, a standardised food substitution list was developed prior to enrolment. Substitute foods were matched by type (fruits, vegetables, legumes, grains, spices, and so on) and ubiquity (common/uncommon foods). Second-choice, third-choice, fourth-choice, and fifth-choice foods were noted in the substitution list to account for instances where preceding foods were restricted. Substitution choices were limited to the 200 items in the test food bank (see online supplementary appendix 1 for the food substitution list).

For participants randomised to the comparison diet, the food substitution list was used to develop an elimination diet that matched the rigour (ie, number of foods to eliminate) and complexity (range of foods) as the 'true' test results. Thus, the list of foods designated as positive or mild to the dietitian was actually foods from the negative list in the participants' test results. The dietitians counselled all participants in the same manner without knowledge of true test results. Thus, each participant received an individualised elimination diet either consistent with (intervention) or systematically inconsistent with (comparison) test results.

Statistical methods

Analyses were conducted using Stata V.14.1. Individual changes between baseline and week 4 were computed for each outcome and tested for whether the mean change observed in the intervention and comparison groups differed significantly ($\alpha=0.05$) using independent t-tests. Distributions of change across time were tested for equality between the intervention and comparison groups using Wilcoxon rank-sum tests. The t-tests have more statistical power, while the Wilcoxon rank-sum tests are more robust to non-normality of the underlying distributions. Effect sizes (Cohen's D) were calculated as the mean difference in changes across time between groups divided by the pooled SD of changes across time. The same analyses were performed for changes between baseline and week 8. Analyses followed the intention-to-treat principle.

Proteomic data were analysed by paired t-tests ($\alpha=0.05$). To account for multiple comparisons, a Benjamini-Hochberg correction with a false detection rate at 0.3 and significance threshold at 0.05 was applied.

After study completion and locking the database, all authors had access to the study data and had reviewed and approved the final manuscript.

RESULTS

Participants were recruited from Connecticut from primary care and specialty practices, newsletter announcements, flyer postings, and electronic media, including *clinicaltrials.gov* and university (*yalestudies.org*) sites.

Of 126 volunteers screened, 68 were not eligible or declined to participate. Fifty-eight participants were randomised between July 2014 and November 2015. One participant, randomised to intervention, declined to participate as new employment resulted in a lack of time to participate. Two other participants (randomised to

intervention) left due to participant burden (one prior to week 4 and one between weeks 4 and 8). All 29 participants in the comparison group completed the study. Thus, 56 participants (97%) remained for the week 4 analysis and 55 participants (95%) remained for the week 8 analysis. The final follow-up visit (8 weeks) occurred in January 2016. The trial ended once the predetermined sample size (58) was achieved. There were no missing data (see [figure 1](#)).

Baseline characteristics are in [table 1](#) showing no significant between-group differences. [Table 2](#) notes the most frequently restricted foods. Participants were restricted from a mean of 13 foods (SD=6), out of 200 possible test foods. During the 4-week dietary period, participants consumed restricted foods at a mean of 2.46 (SD=4)

Figure 1 CONSORT flow diagram.

Table 1 Demographics and baseline characteristics

	Intervention (n=29)	Comparison (n=29)
Age	38±13	38±15
Female, n (%)	28 (97)	27 (93)
White, n (%)	28 (97)	25 (86)
Body mass index (kg/m ²)	25.90±6.26	24.84±5.09
Adequate Relief	0.14±0.36	0.21±0.41
Global Improvement Scale (GIS)	-0.29±1.21	0.17±0.76
Symptom Severity Scale (SSS)	269±68	261±91
Quality of Life (QOL)	39±17	42±19
Taking medications for IBS, n (%)	6 (21)	2 (7)
Taking antidepressants, n (%)	6 (21)	7 (24)
IBS subtype ¹⁵		
IBS-C (n)	4	6
IBS-D (n)	3	4
IBS-M (n)	4	9
IBS-U (n)	18	10

All values are mean±SD, unless otherwise noted. Baseline differences in means were assessed with t-tests for quality of life, SSS and body mass index, while differences in distributions of GIS were determined by Wilcoxon rank-sum testing.

IBS, irritable bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhoea; IBS-M, mixed IBS; IBS-U, unsubtyped IBS.

times. Overall rates of adherence are statistically indistinguishable ($p=0.26$) between intervention and comparison groups. Seven participants consumed restricted foods more than four times, and three participants consumed restricted foods more than eight times.

Primary outcome: IBS-GIS

Intention-to-treat analysis

The intervention diet resulted in a statistically significant change over time in GIS between the intervention ($n=27$) and comparison ($n=29$) diet at 4 weeks with a mean between-group difference equal to 0.86 ($p=0.04$, 95% CI 0.05 to 1.67). The significant improvement in the GIS in the intervention group persisted at 8 weeks with the mean between-group difference equal to 1.22 ($p=0.02$, 95% CI 0.22 to 2.22) (see [table 3](#) and [figure 2](#)).

Secondary outcomes

Intention-to-treat analysis

Both the intervention and comparison groups demonstrated significant improvements from baseline in SSS, with the intervention group experiencing significantly larger improvements. The mean between-group difference in change since baseline at 4 weeks was -61.78 ($p=0.04$, 95% CI -4.43 to -119.14), and the mean between-group difference in change since baseline at 8

Table 2 Foods most frequently restricted during the 4-week diet ($n=58$)

Food	Frequency n (%)	High FODMAP
Strawberry	15 (26)	
Cinnamon	15 (26)	
Almond	12 (21)	X
Apple	12 (21)	X
Onion	12 (21)	X
Pear	11 (19)	X
Buckwheat	11 (19)	
Chickpea	11 (19)	
Ginger	11 (19)	
Raspberry	11 (19)	
Blueberry	10 (17)	
Hops	10 (17)	
Oats	10 (17)	
Olive	10 (17)	
Quinoa	10 (17)	
Sorghum	10 (17)	
Yellow squash	10 (17)	

Foods occurring more than 10 times (out of 58 participants) are listed. High FODMAP foods, categorised by the Monash University low-FODMAP diet app.⁴⁶

FODMAP, fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols.

weeks was -66.42 ($p=0.03$, 95% CI -5.75 to -127.09) (see [table 3](#) and [figure 2](#)).

There were no statistically significant between-group differences in the change over time for IBS-AR and IBS-QOL at 4 weeks or 8 weeks (see [table 3](#) and [figure 2](#)).

No adverse effects related to the intervention were reported. Two instances of syncope related to blood draw occurred.

Ancillary analyses

Levels of adherence

To assess whether dietary adherence affected outcomes, the sample was divided into *higher adherence* (eating restricted foods two or fewer times) and *lower adherence* (eating restricted foods three or more times) over the course of the 4-week intervention period, resulting in an approximately 50–50 distribution (median-split analysis). No significant differences were found between the adherence subsamples and the full sample.

Effect of dietitians

The original study dietitian (AS) had a leave of absence during the course of the study (after 35 participants), and was replaced by a second dietitian (SK). Effects were estimated separately for participants counselled by each dietitian. No significant differences between dietitians were found.

Table 3 Treatment outcomes

	Intervention	Comparison	Difference (95% CI)	Effect size (Cohen's D)	p Value*
	(n=29)	(n=29)			
Number of foods restricted	13.6±5.9	12.7±6.0			0.58
4 weeks—primary endpoint	(n=27)	(n=29)			
GIS	1.9±1.2	1.1±1.5	0.86 (0.05 to 1.67)	0.55	0.04†/0.04†
AR	0.6±0.5	0.5±0.5	0.15 (−0.14 to 0.43)	0.27	0.31/0.35
SSS reduction	121±97	60±101	61.78 (4.43 to 119.14)	0.56	0.04†/0.05†
QOL improvement	17±19	18±15	0.45 (−7.98 to 8.87)	0.03	0.92/0.88
8 weeks	(n=26)	(n=29)			
GIS	1.8±1.6	0.6±1.7	1.22 (0.22 to 2.22)	0.63	0.02†/0.04†
AR	0.5±0.5	0.3±0.5	0.19 (−0.11 to 0.49)	0.34	0.22/0.26
SSS reduction	116±104	50±102	66.42 (5.75 to 127.09)	0.57	0.03†/0.05†
QOL improvement	19.3±18.5	15.2±17.6	−4.12 (−14.46 to 6.22)	0.22	0.43/0.30

All values are means ±SD, unless otherwise noted. Changes between baseline and the week 4/week 8 time points were computed for all outcomes and tested for whether the mean change observed in the intervention and comparison groups was significantly different ($\alpha=0.05$) for each measure using independent t-tests. The distributions of changes across time were also tested for equality in the intervention and comparison groups using Wilcoxon rank-sum tests.

*p Values are from independent t-tests and Wilcoxon rank-sum tests.

†Statistically significant at $\alpha=0.05$.

AR, IBS Adequate Relief Scale; GIS, IBS Global Improvement Scale; IBS, irritable bowel syndrome; QOL, IBS Quality of Life Questionnaire; SSS, IBS Symptom Severity Scale.

Sensitivity analysis

To account for potential bias induced by non-random attrition, effects of the treatment were re-estimated on the entire baseline sample under the assumption that those who discontinued treatment would have experienced zero effect of the treatment. One individual dropped out of the study before week 4, and two dropped out before week 8. Between-group differences in GIS and SSS remained statistically significant.

Placebo effects

As placebo effects have been shown to increase with more invasive interventions,^{26 27} we assessed the effects of the number of restricted foods versus change in the IBS-SSS (our continuous measure). No association was found between the number of restricted foods and change in IBS-SSS scores in both the intervention group ($p=0.70$) and in the control group ($p=0.82$).

Proteomic data

In paired analysis of the 12 plasma samples, concentrations of 87 of the 1128 proteins were significantly different ($p<0.05$) between baseline and week 4 samples. To correct for multiple comparisons, these data were analysed with a Benjamini-Hochberg procedure.²⁸ After this correction, a significant pre–post difference in a single

protein (neutrophil elastase) was found to be reduced in strong responders.

DISCUSSION

In this study, statistically significant benefits were seen in the primary outcome of global improvement, as well as in symptom severity in a 4-week diet guided by leucocyte activation testing compared with a matched sham diet²⁹ in an adequately powered sample of 58 participants with IBS. While quality of life and adequate relief both improved, statistically significant between-group differences were not seen. Both groups demonstrated significant improvements from baseline. Thus, a substantial intervention effect and a substantial placebo effect were seen, with the intervention effect significantly better than placebo in global improvement and symptom severity, with effect sizes³⁰ of medium magnitude.

Furthermore, between-group differences in global improvement and symptom severity remained statistically significant at 8 weeks postbaseline (4 weeks after the dietary intervention), as participants noted adhering to aspects of the elimination diet (during the ad libitum phase between weeks 4 and 8) consistent with achieving symptomatic relief.

Figure 2 Change from baseline in global improvement, symptom severity, adequate relief, and quality of life. IBS-GIS indicates the Irritable Bowel Syndrome Global Improvement Scale; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale; IBS-AR, Irritable Bowel Syndrome Adequate Relief; and IBS-QOL, Irritable Bowel Syndrome Quality of Life Questionnaire. Values are expressed as mean change. Positive scores denote improvement. The intervention group demonstrated significantly larger between-group improvement than the comparison group in the (A) GIS at 4 weeks (1.93 vs 1.07; ES 0.55, $p=0.04$; $n=56$ —primary endpoint) and 8 weeks postbaseline (1.81 vs 0.59; ES 0.63, $p=0.02$; $n=55$), and (B) SSS at 4 weeks (121.4 vs 59.6; ES 0.56, $p=0.04$) and 8 weeks (116.4 vs 50.0; Effect Size (Cohen's D) (ES) 0.57, $p=0.03$) postbaseline. No significant between-group differences were seen in the (C) AR and (D) QOL scales. Relative to baseline, all outcomes improved in both groups at 4 weeks and 8 weeks.

These findings reject the null hypothesis and show that a diet guided by leucocyte activation testing results in demonstrable clinical improvement in IBS. These clinical results, associated with a reduction in plasma neutrophil elastase, have implications for better understanding the role of food intolerance and the pathophysiology of IBS.

Strengths of this study include an adequately powered,³ randomised design^{32,33} with a matched comparison diet utilising a rigorous blinding strategy, validated outcome measures, an intention-to-treat analysis,³⁴ high levels of dietary adherence, and minimal dropout, all of which can reduce bias in making valid statistical inferences.³¹ Sample size calculations were based on a previous study of placebo interventions,¹⁹ thus accounting for substantial placebo effects seen in IBS clinical trials.³⁵ Furthermore,

mechanistic correlates and sensitivity analyses corroborated the intention-to-treat findings. This study was designed, conducted, and analysed completely independent of the sponsor,³⁶ and preregistered on *ClinicalTrials.gov*.³⁷

Limitations of this study include self-report instruments for clinical outcomes, an ethnically homogeneous population, as well as a relatively short intervention period of 4 weeks. This 4-week intervention was chosen to maximise internal validity, as adherence to behavioural interventions wanes over time,³⁸ and previous trials have found significant changes in these outcomes over a 3-week period.¹⁹ Furthermore, other factors that can affect IBS symptoms were not accounted for, such as the gut microbiota,³⁹ psychological stress,^{8,39,40} or travel.⁴¹ Nevertheless, adequate

randomisation controls for potential confounding factors, known and unknown.⁴²

While the prior literature assessing specific elimination diets for IBS has shown conflicting results,^{4 43} a dietary pattern restricting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has shown promise as an efficacious, although burdensome, dietary intervention for IBS.^{4 44} Indeed, the magnitude of improvement in SSS scores (mean 121 points in intervention participants, 60 points in comparison participants) compares favourably with participants consuming a low-FODMAP diet (mean change of 78 points) in a recent randomised trial.⁴⁵ In contrast to the broad restrictions imposed by the low-FODMAP diet, this study finds significant effects from individualised diets based on results from a leucocyte activation test. As seen in table 2, there was infrequent overlap between test-positive foods and high-FODMAP foods,⁴⁶ as well as no significant differences in the frequency of restriction of high-FODMAP foods between intervention and control groups. Future studies can directly assess clinical response based on leucocyte activation testing compared with low-FODMAP diets.

This study provided an opportunity to further investigate biological factors associated with IBS. Diet may impact the course of IBS through effects on the microbiome, immune activation, intestinal permeability,^{8 47} brain–gut interactions,^{8 39 40} and motility.⁷ Indeed, some study participants reported exacerbations of IBS symptoms during stressful periods. The breadth of these potential factors makes it difficult to develop a hypothesis-based approach that would investigate one or a few biological factors. To circumvent this challenge, a broad proteomic screen was used that found a reduction in plasma elastase in strong responders to the intervention diet.⁴⁸

This finding is of interest as elastase is widely distributed in innate immune cells, including in neutrophils and mast cells. Mast cells are of particular interest as they have been shown to be increased in close approximation to nerves in the colonic mucosa.^{49 50} Mast cell mediators such as tryptase and histamine are increased in the colon of patients with IBS.⁴⁹ Elastase can cause tissue damage and also disrupt tight junctions, which may increase intestinal permeability.⁵¹ The validity of the clinical results is not dependent on the proteomic data, which may however provide mechanistic insights. Future studies can investigate mechanistic factors in greater detail.

In a related study, positive responses in leucocyte activation testing (in healthy controls) were associated with greater magnitudes of DNA release, but not myeloperoxidase release, mediated by protein kinase C and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways. Furthermore, test-positive foods were associated with CD63 upregulation in eosinophils compared with test-negative foods.⁵²

It is noteworthy that participants consuming a sham diet improved from baseline. Non-specific,

contextual, and placebo responses tend to be high in IBS.^{35 53 54} Indeed, Kaptchuk and Lembo demonstrated the utility of open-label placebos in IBS.¹⁹ Placebo interventions involving a therapeutic ritual, such as an elaborate dietary change, may affect subjective symptomatology to a greater extent versus simple placebos, such as pills.^{26 27} It is also possible that comparison group outcomes reflect a combination of beneficial placebo combined with deleterious effects of consuming presumably intolerant foods in the elimination diet. Nevertheless, between-group differences in the GIS and SSS were approximately double in the intervention group compared with the comparison group. Furthermore, we found no evidence to indicate that the rigour of the intervention (number of restricted foods) was associated with greater improvements.

In summary, this study provides data suggesting that a leucocyte activation test can be used to develop an individualised diet that can alleviate symptom burden in IBS. These dietary changes may be less restrictive than a low-FODMAP diet, and may result in better long-term adherence. Future studies, ideally multisite and in larger samples, can assess comparative effects of other dietary interventions in IBS, the effects of restricting specific foods, and whether dietary changes guided by leucocyte activation testing affect other conditions.

Acknowledgements We thank Eugene D Shapiro MD, Gowri Ananthanarayanan MS, David Brady ND DC, Evangelos Dioletis PhD, Changchuan (Charles) Jiang MD MPH, Irma Garcia Martinez PhD, Seth M Luty MS, Kristin DeFrancesco BS, Nicholas Licht MBA, Theresa Katz, and Julia O'Sullivan ND MS for their technical support and assistance, and extend special thanks to Yvette Strong and Irene Matos RN for their kind care and laboratory assistance during participant visits. We are especially grateful to our study participants.

Contributors AA designed the study, drafted the manuscript, obtained funding, interpreted the data and was responsible for overall supervision of the study. He has full access to all the data in the study, but was blinded until study completion. TRW was involved with the acquisition of data, critical revision of the manuscript for important intellectual content, administrative support and supervision of the clinical staff. DM conducted and is responsible for the data analysis, statistical analysis and critical revision of the manuscript for important intellectual content. AS and SK were involved with the acquisition of the data. MRF was involved with data analysis and critical revision of the manuscript. DA was involved with the design of the study. WZM was involved with the conception and design of the study, statistical analysis, interpretation of the data and critical revision of the manuscript for important intellectual content. WZM and AA take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This study was funded by Cell Science Systems, Corp. (Deerfield Beach, FL). The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This publication used resources from CTSA Grant Number UL1 TR000142 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

Competing interests None declared.

Patient consent Obtained.

Ethics approval Human Investigation Committee of Yale University.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures and appendices),

and/or the study protocol will be shared beginning 9 months and ending 36 months after article publication. Data will be shared with investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for these purposes: (1) for individual participant data meta-analysis, and (2) researchers who provide a methodologically sound proposal. Proposals should be directed to ather.ali@yale.edu. To gain access, data requestors will need to sign a data access agreement.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Hungin AP, Chang L, Locke GR, *et al*. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Aliment Pharmacol Ther* 2005;21:1365–75.
- Gaman A, Bucur MC, Kuo B. Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome. *Therap Adv Gastroenterol* 2009;2:169–81.
- Simrén M, Månsson A, Langkilde AM, *et al*. Food-related gastrointestinal symptoms in the irritable bowel syndrome. *Digestion* 2001;63:108–15.
- Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. *Gastroenterol Hepatol* 2012;8:739–45.
- Gibson PR, Varney J, Malakar S, *et al*. Food components and irritable bowel syndrome. *Gastroenterology* 2015;148:1158–74.
- Farah DA, Calder I, Benson L, *et al*. Specific food intolerance: its place as a cause of gastrointestinal symptoms. *Gut* 1985;26:164–8.
- Chey WD. Food: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome. *Am J Gastroenterol* 2016;111:366–71.
- Enck P, Aziz Q, Barbara G, *et al*. Irritable bowel syndrome. *Nat Rev Dis Primers* 2016;2:16014.
- Bernstein M, Day JH, Welsh A. Double-blind food challenge in the diagnosis of food sensitivity in the adult. *J Allergy Clin Immunol* 1982;70:205–10.
- Bengtsson U, Nilsson-Balknäs U, Hanson LA, *et al*. Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms. *Gut* 1996;39:130–5.
- Atkinson W, Sheldon TA, Shaath N, *et al*. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. *Gut* 2004;53:1459–64.
- Teuber SS, Beyer K. IgG to foods: a test not ready for prime time. *Curr Opin Allergy Clin Immunol* 2007;7:257–8.
- Ali A, Scoulios N, Ten N, *et al*. A National Assessment of the Usage, Cost, and Reimbursement of Unconventional Medical Laboratory Tests. *The Journal of Alternative and Complementary Medicine* 2014;20:A3–A4.
- Wüthrich B. Unproven techniques in allergy diagnosis. *J Investig Allergol Clin Immunol* 2005;15:86–90.
- Longstreth GF, Thompson WG, Chey WD, *et al*. Functional bowel disorders. *Gastroenterology* 2006;130:1480–91.
- Lembo T, Wright RA, Bagby B, *et al*. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol* 2001;96:2662–70.
- Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther* 1997;11:395–402.
- Bijkerk CJ, de Wit NJ, Muris JW, *et al*. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. *Am J Gastroenterol* 2003;98:122–7.
- Kaptschuk TJ, Friedlander E, Kelley JM, *et al*. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. *PLoS One* 2010;5:e15591.
- Johannesson E, Ringström G, Abrahamsson H, *et al*. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. *World J Gastroenterol* 2015;21:600–8.
- Lembo AJ, Conboy L, Kelley JM, *et al*. A treatment trial of acupuncture in IBS patients. *Am J Gastroenterol* 2009;104:1489–97.
- Pedersen N, Andersen NN, Végh Z, *et al*. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. *World J Gastroenterol* 2014;20:16215–26.
- Wang XX, Luo RJ, She B, *et al*. Traditional Chinese medicine (Shun-Qi-Tong-Xie Granule) for irritable bowel syndrome: study protocol for a randomised controlled trial. *Trials* 2014;15:273.
- Passos MC, Lembo AJ, Conboy LA, *et al*. Adequate relief in a treatment trial with IBS patients: a prospective assessment. *Am J Gastroenterol* 2009;104:912–9.
- Drossman DA, Patrick DL, Whitehead WE, *et al*. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. *Am J Gastroenterol* 2000;95:999–1007.
- Finniss DG, Kaptschuk TJ, Miller F, *et al*. Biological, clinical, and ethical advances of placebo effects. *Lancet* 2010;375:686–95.
- Benedetti F. Placebo and the new physiology of the doctor-patient relationship. *Physiol Rev* 2013;93:1207–46.
- Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B* 1995;57:289–300.
- Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. *Am J Gastroenterol* 2013;108:748–58.
- Cohen J. *Statistical power analysis for the behavioral sciences*. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates, 1988.
- Levine RJ. *Ethics and Regulation of Clinical Research*. 2nd ed. New Haven: Yale University Press, 1986.
- Katz DL, Jekel JF. *Jekel's epidemiology, biostatistics, preventive medicine, and public health*. 4th ed. Philadelphia; London: Saunders, 2014.
- Delgado-Rodriguez M, Bias LJ. *J Epidemiol Community Health* 2004;58:635–41.
- Peduzzi P, Henderson W, Hartigan P, *et al*. Analysis of randomized controlled trials. *Epidemiol Rev* 2002;24:26–38.
- Elsenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. *Nat Rev Gastroenterol Hepatol* 2015;12:472–85.
- Lexchin J, Bero LA, Djulbegovic B, *et al*. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. *BMJ* 2003;326:1167–70.
- Rodwin MA, Abramson JD. Clinical trial data as a public good. *JAMA* 2012;308:871–2.
- Courneya KS. Efficacy, effectiveness, and behavior change trials in exercise research. *Int J Behav Nutr Phys Act* 2010;7:81.
- Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. *J Clin Invest* 2015;125:926–38.
- Buckley MM, O'Mahony SM, O'Malley D. Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome. *World J Gastroenterol* 2014;20:8846–58.
- Steffen R, Hill DR, DuPont HL. Traveler's diarrhea: a clinical review. *JAMA* 2015;313:71–80.
- Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001;323:42–6.
- Gibson PR. Food intolerance in functional bowel disorders. *J Gastroenterol Hepatol* 2011;26 Suppl 3(Suppl 3):128–31.
- Eswaran SL, Chey WD, Jackson K, *et al*. 821 A Low FODMAP Diet Improves Quality of Life, Reduces Activity Impairment, and Improves Sleep Quality in Patients With Irritable Bowel Syndrome and Diarrhea: Results From a U.S. Randomized, Controlled Trial. *Gastroenterology* 2016;150:S172.
- Böhn L, Störsrud S, Liljebo T, *et al*. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. *Gastroenterology* 2015;149:1399–407.
- Monash University. The Monash University Low FODMAP Diet, 2016. (Version 2.0.1) (Mobile application software). <http://itunes.apple.com/>
- Bischoff SC, Barbara G, Buurman W, *et al*. Intestinal permeability--a new target for disease prevention and therapy. *BMC Gastroenterol* 2014;14:189.
- Lollo B, Steele F, Gold L. Beyond antibodies: new affinity reagents to unlock the proteome. *Proteomics* 2014;14:638–44.
- Barbara G, Stanghellini V, De Giorgio R, *et al*. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004;126:693–702.
- Park CH, Joo YE, Choi SK, *et al*. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. *J Korean Med Sci* 2003;18:204–10.

51. Ginzberg HH, Cherapanov V, Dong Q, *et al.* Neutrophil-mediated epithelial injury during transmigration: role of elastase. *Am J Physiol Gastrointest Liver Physiol* 2001;281:G705–17.
52. Garcia-Martinez I, Weiss T, Ali A, *et al.* The Alcat Test Predicts the Release of DNA and Myeloperoxidase by Innate Immune Peripheral Blood Leukocytes via a PKC Dependent Pathway. *J Altern Complement Med* 2016:A23.
53. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. *Aliment Pharmacol Ther* 2010;32:144–58.
54. Patel SM, Stason WB, Legedza A, *et al.* The placebo effect in irritable bowel syndrome trials: a meta-analysis. *Neurogastroenterol Motil* 2005;17:332–40.